HRP20130642T1 - Methods and compositions for treating cancers - Google Patents

Methods and compositions for treating cancers

Info

Publication number
HRP20130642T1
HRP20130642T1 HRP20130642AT HRP20130642T HRP20130642T1 HR P20130642 T1 HRP20130642 T1 HR P20130642T1 HR P20130642A T HRP20130642A T HR P20130642AT HR P20130642 T HRP20130642 T HR P20130642T HR P20130642 T1 HRP20130642 T1 HR P20130642T1
Authority
HR
Croatia
Prior art keywords
compositions
methods
treating cancers
cancers
treating
Prior art date
Application number
HRP20130642AT
Other languages
English (en)
Inventor
Christine Dierks
Markus Warmuth
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of HRP20130642T1 publication Critical patent/HRP20130642T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20130642AT 2007-08-16 2013-07-08 Methods and compositions for treating cancers HRP20130642T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95629507P 2007-08-16 2007-08-16
PCT/US2008/073049 WO2009026075A1 (en) 2007-08-16 2008-08-13 Methods and compositions for treating cancers

Publications (1)

Publication Number Publication Date
HRP20130642T1 true HRP20130642T1 (en) 2013-08-31

Family

ID=40210407

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130642AT HRP20130642T1 (en) 2007-08-16 2013-07-08 Methods and compositions for treating cancers

Country Status (16)

Country Link
US (3) US20100216828A1 (hr)
EP (1) EP2187967B1 (hr)
JP (1) JP2010536775A (hr)
KR (1) KR20100056525A (hr)
CN (1) CN101820915A (hr)
AU (1) AU2008289255B2 (hr)
BR (1) BRPI0815330A2 (hr)
CA (1) CA2699988A1 (hr)
DK (1) DK2187967T3 (hr)
ES (1) ES2422285T3 (hr)
HR (1) HRP20130642T1 (hr)
MX (1) MX2010001813A (hr)
PL (1) PL2187967T3 (hr)
RU (1) RU2010109452A (hr)
SI (1) SI2187967T1 (hr)
WO (1) WO2009026075A1 (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110117212A1 (en) * 2008-07-24 2011-05-19 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent
US20110039850A1 (en) * 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
KR101853596B1 (ko) * 2009-10-23 2018-04-30 노파르티스 아게 Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법
WO2013187967A1 (en) * 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
CN103768067A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
CN104262262B (zh) * 2014-08-29 2016-06-08 西安交通大学 一种N,6二苯基嘧啶-4-胺类Bcr-Abl抑制剂及其制备方法和应用
CN109744199A (zh) * 2017-11-08 2019-05-14 南京艾莫瑞生物科技有限公司 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用
EP3624798A1 (en) * 2017-05-18 2020-03-25 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of mast cell diseases
CN108721217B (zh) * 2018-08-21 2020-09-08 武汉轻工大学 抗肿瘤药物组合物及药物制剂和应用
US20200297725A1 (en) * 2019-03-22 2020-09-24 Yale University Allosteric bcr-abl proteolysis targeting chimeric compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
ATE404200T1 (de) 2002-04-22 2008-08-15 Univ Johns Hopkins Med Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
EA017262B1 (ru) 2004-09-02 2012-11-30 Дженентек, Инк. Соединения 2-(2-галоген-4-аминофенил)пиридиновых ингибиторов передачи сигналов белком hedgehog (варианты), способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе
WO2006102611A2 (en) * 2005-03-24 2006-09-28 The Ohio State University Research Foundation Therapeutic agents for the treatment of leukemia

Also Published As

Publication number Publication date
MX2010001813A (es) 2010-03-10
US20100216828A1 (en) 2010-08-26
PL2187967T3 (pl) 2013-09-30
JP2010536775A (ja) 2010-12-02
CA2699988A1 (en) 2009-02-26
ES2422285T3 (es) 2013-09-10
AU2008289255A1 (en) 2009-02-26
BRPI0815330A2 (pt) 2017-05-09
EP2187967A1 (en) 2010-05-26
AU2008289255B2 (en) 2012-02-02
WO2009026075A1 (en) 2009-02-26
US20120165355A1 (en) 2012-06-28
CN101820915A (zh) 2010-09-01
DK2187967T3 (da) 2013-07-22
SI2187967T1 (sl) 2013-07-31
RU2010109452A (ru) 2011-09-27
EP2187967B1 (en) 2013-04-24
US20130210771A1 (en) 2013-08-15
KR20100056525A (ko) 2010-05-27

Similar Documents

Publication Publication Date Title
IL257681A (en) Methods and compositions for the treatment of cancer
HRP20160949T1 (hr) Novi sastavi i metode za liječenje karcinoma
SI2173379T1 (sl) Sestavki in postopki za zdravljenje in diagnosticiranje raka
HK1140944A1 (en) Methods and compositions for treating recurrent cancer
EP2125887A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
IL218987A0 (en) Methods and compositions for treating cancer
ZA200901615B (en) Compositions and methods for diagnosing and treating cancer
PL2032166T3 (pl) Kompozycje i sposoby diagnozowania i leczenia nowotworów
EP2214707A4 (en) COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION
EP2124985A4 (en) METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS
HRP20130642T1 (en) Methods and compositions for treating cancers
EP2155249A4 (en) COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER
IL210097A0 (en) Compositions and methods for treating unfluenza
EP2419136A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2176406A4 (en) COMPOSITIONS AND METHOD FOR CANCER TREATMENT
IL204945A0 (en) Compositions and methods for inhibiting tumor progression
IL199881A0 (en) Compositions and methods for treating hematopietic malignancies
EP2150270A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
EP2137213A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER
EP2099491A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER
EP2252298A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF LUNG CANCER
EP2200627A4 (en) METHOD AND COMPOSITIONS FOR TREATING MELANOMA
EP2068629A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
SI3067054T1 (sl) Novi sestavki in postopki za zdravljenje raka
LT3067054T (lt) Naujos kompozicijos ir būdai vėžiui gydyti